Further analysis showed that patients with a high overall risk of HF (i.e., a history of HF, impaired renal function, or elevated baseline levels of N-Terminal proBNP) were more susceptible to the detrimental effects of the DPPIV inhibitor [146]. This evidence concerns the gene DPP4 and hydrops fetalis.